Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Forma Therapeutics, J&J, Cancer Research U.K. deal

Forma partnered with not-for-profit Cancer Research's Cancer Research Technology commercial arm to develop compounds against deubiquitinating enzymes (DUBs) for cancer indications. Forma will work with an initial group of

Read the full 291 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE